ABO2011 not checked

Suzhou Abogen Biosciences Co., Ltd. · ABOD2011

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection”In the company’s words, NCT06088004 on ClinicalTrials.gov
Tested for
Solid Tumor, Adult
Main trialPhase 1/2
“This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.”In the company’s words, NCT06088004 on ClinicalTrials.gov
Other names
ABOD2011

Other drugs for Solid Tumor, Adult

All 2440 drugs for Solid Tumor, Adult

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 30 Dec 2026 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ABO2011

Following is part of Solo: you see every change to ABO2011 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in